The ASXL1 Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, in which the gene encoding the additional sex combs-like 1 (ASXL1) chromatin regulator has been disrupted. This heterogeneous pool contains cells with diverse CRISPR-mediated gene-editing events, collectively yielding a functional ASXL1 loss-of-function model. The polyclonal nature offers a robust and representative system for studying ASXL1-dependent biology without the limitations of clonal selection.
The A-549 host cell line is a hypotriploid human alveolar basal epithelial cell line isolated from a 58-year-old Caucasian male with lung carcinoma. This adherent cell line is widely employed as a model for type II pneumocytes and non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma. A-549 cells retain key characteristics of alveolar epithelia and exhibit well-characterized signaling networks, making them an ideal platform for investigating oncogenic drivers and epigenetic mechanisms in lung cancer.
ASXL1 encodes an essential scaffolding protein that functions as an epigenetic regulator within the Polycomb repressive deubiquitinase (PR-DUB) complex. It directly interacts with the catalytic subunit BAP1 to remove monoubiquitin from histone H2A at lysine 119 (H2AK119ub1), thereby opposing Polycomb repressive complex 1 (PRC1)-mediated transcriptional silencing. ASXL1 forms complexes with core PRC2 components EZH2, SUZ12, and EED, and interacts with transcriptional co-regulators such as nuclear hormone receptors (AR, ER??) and NCOA1. Signaling pathways including Notch and TGF-?? converge on ASXL1, with upstream regulators like RUNX1 modulating its activity, while downstream targets encompass HOX gene clusters, CDKN2A, and Notch effectors HES1 and HEY1.
In the A-549 background, knockout of ASXL1 leads to persistent hyperubiquitination of H2AK119ub1, reflecting loss of PR-DUB deubiquitinase function. This epigenetic derangement alters chromatin architecture at Polycomb target loci, dysregulating gene expression programs involved in cell cycle control, apoptosis, and lineage specification. The resulting phenotype mimics aspects of ASXL1 somatic mutations documented in lung adenocarcinoma, establishing this model as a physiologically relevant tool to dissect the contribution of ASXL1 to tumorigenesis and to explore therapeutic vulnerabilities linked to chromatin dysregulation.
Researchers can employ this polyclonal knockout cell population in a broad array of experimental applications. ChIP-qPCR enables profiling of H2AK119ub1 and other histone modifications at specific genomic loci, while RNA-seq captures global transcriptomic changes. Protein-level analyses via Western blotting and co-immunoprecipitation validate ASXL1 complex integrity and downstream signaling. Functional assays??including proliferation, colony formation, and apoptosis measurements??enable assessment of cancer-relevant phenotypes. This model is suited for epigenetic drug target validation, synthetic lethality screens, and mechanistic dissection of the PR-DUB complex in solid tumors. For further information or inquiries, please contact Ascent Research.
